I arrived at a similar conclusion Muse but I'm probably less concerned about the patent expiry. I suspect where maxigesic is mature it has brand value and people buy it mainly out of habit as that's what they always buy when they're sick. Whether it's still under patent or not I'm not sure would get noticed by the usual buyer, at least for ANZ.
I violated their patent the other day when I took a Panadol and ibuprofen together - oops.
I have this on my watch list, but I am struggling to come up with the right time to buy given the downward pressure. I see no announcement anywhere to add downwards pressure....
I bought around $3.90 quite a while back. Sold recently at $3.30. Have always being sceptical on the maxigesic oral and iv* forms but thought they would plug a whole lot of other gaps in the generic supply market which continues to be problematic. Not to be! Back on Watchlist. *I think they have a product for a market that doesn’t exist. Better options are available.
Strange. My calculator tells me the average purchase price paid over the last 3 months for the 1.152m shares acquired was $2.60. The SPH Notice states the purchases were on market but the price only drifted down and reached $2.60 briefly a day or two ago. So may be all were earlier this week?
Bookmarks